Last deal
Amount
Stage
Date
all rounds
Total amount
date founded
Financing round
General
About Company
Industry
Sector :
Subsector :
Keywords :
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
Similar Companies999
Spring Pharmaceuticals
Spring Pharmaceuticals is a biotechnology company based in Duncan, South Carolina, focused on developing innovative cancer therapies.
Sector
Subsector
Keywords
Location
total rounds
total raised
Adriacell
Adriacell is a biotech company focused on developing solutions for tumors with low survival rates and anti-infective agents.
Sector
Subsector
Keywords
Location
EOS (Ethical Oncology Science)
EOS is a biopharmaceutical company focused on developing innovative cancer treatments.
Sector
Subsector
Keywords
Location
total rounds
total raised
GPC Biotech
GPC Biotech is a German biopharmaceutical company developing anticancer drugs.
Sector
Subsector
Location
M&A Details1
Financials
Funding Rounds2
Co-Investors
Investors4
Number of lead investors
Number of investors
MPM Capital
MPM Capital invests in early-stage healthcare companies developing innovative oncology technologies.
Sector
Subsector
Location
count Of Investments
count Of Exists
Johnson & Johnson Development Corporation
JJDC is the venture capital arm of Johnson & Johnson, investing in pharmaceuticals, medical devices, and consumer healthcare.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Partners Innovation Fund
The Innovation Fund accelerates healthcare technology development and attracts external capital.
Sector
Subsector
Location
count Of Investments
count Of Exists
People
Founders2
Robert Millman
Robert Millman brings to MPM 20 years of experience in creating and managing intellectual property and patent estates for biotechnology and drug discovery and development companies. Prior to joining MPM Capital, he was the Chief IP Counsel for Alnylam Pharmaceuticals Inc., where he developed the leading intellectual property portfolio in RNAi therapeutics. Prior to Alnylam, for three years he served as the Chief IP Counsel at Infinity Pharmaceuticals, Inc., a company focused on small molecule discovery. From 1999 to 2002, Mr. Millman was Chief IP Counsel at Celera Genomics, where he developed and implemented an IP protection plan during the race to sequence the human genome. Mr. Millman has previously served as Patent Counsel at Millennium Pharmaceuticals, Inc., and earlier in his career; he held an associate position at Morrison and Foerster LLP and a patent agent/specialist position at Sterne, Kessler Goldstein and Fox, LLP. Mr. Millman received his J.D. degree from the Washington College of Law at The American University, an M.S. degree in Genetics from Washington State University and a B.S. degree in Biochemistry from the University of California, Riverside.
current job
Robert Millman
Luke Evnin
Luke Evnin is the Co-Founder and Managing Director of MPM Capital.
current job
Luke Evnin